Exelixis (EXEL) is at the ASCO conference in Chicago and over the weekend, they released phase II study results for CABO and its effects on ovarian cancer. Monday afternoon, they will be releasing much anticipated data for CABO’s effects on prostate cancer. Below are the links to bring yourself up to speed if you’ve been trading EXEL at all.
Headlines
- Exelixis cabozantinib exhibits clinical activity in multiple tumor typesat theflyonthewall.com(Sun 4:11PM EDT)
- Exelixis’ Cabozantinib Demonstrates Broad Clinical Activity in Multiple Tumor TypesBusiness Wire(Sun 1:00PM EDT)
- ASCO Conference Blog Recapat TheStreet.com(Sat, Jun 4)
- Exelixis’ Cabozantinib Demonstrates Encouraging Clinical Activity in Patients with Metastatic Ovarian CancerBusiness Wire(Sat, Jun 4)
- ASCO ’11: Exelixis Drug Shrinks Ovarian Cancerat TheStreet.com(Sat, Jun 4)
- ASCO ’11: Roche, Avastin and Ovarian Cancerat TheStreet.com(Sat, Jun 4)
Mike
At the time of publication, Kudrna was Long EXEL but positions may change at any time
